Table 5 Multivariate regression analysis of the factors related to AKI in patients administered L-AMB.

From: Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan

Variables

Odds ratio (95% CI)

P-value

VIF

Patient condition prior to L-AMB treatment

eGFR < 60 mL/min

0.734 (0.407–1.325)

0.305

1.029

Potassium (K) < 3.5 mEq/L

1.165 (0.731–1.858)

0.520

1.034

Patient condition after the initiation of L-AMB treatment

Catecholamine treatmenta

2.315 (1.173–4.569)

0.016

1.040

Treatment before L-AMB therapy

   

ACE inhibitors/ARBs

2.070 (1.120–3.824)

0.020

1.023

Carbapenem

2.034 (1.303–3.176)

0.002

1.057

Concomitant treatment with L-AMB therapy

Immunosuppressants

2.248 (1.083–4.663)

0.030

1.029

Teicoplanin

1.595 (0.880–2.891)

0.124

1.071

Vancomycin

1.540 (0.986–2.405)

0.058

1.062

L-AMB administration

Mean daily dose, ≥ 3.52 mg/kg/day

2.648 (1.302–5.386)

0.007

1.038

  1. Bold font indicates statistically significant variables (p < 0.05). N = 444.
  2. ACE angiotensin-converting enzyme, ARBs angiotensin-receptor blockers, CI confidence interval, eGFR estimated glomerular filtration rate, L-AMB, liposomal amphotericin B.
  3. aCatecholamine treatment was defined as the state of shock.
Back to article page